School of Medicine
Showing 1-20 of 69 Results
Javier Ajenjo Barcenas
Postdoctoral Scholar, Molecular Imaging Program at Stanford
BioJavier received his MSci from the University Complutense in Madrid (Spain). He then moved to Prague (Czech Republic) where he earned his PhD degree in Chemistry from Univerzita Karlova under the supervision of Dr Petr Beier at IOCB, working on the synthesis and derivatization of hypervalent sulfur fluorides. During this period, he also took part as ESR of FLUOR21 initial training network led by Prof Graham Sandford (Durham University) and collaborated with F2 Chemicals Ltd. Later, he joined the University of Oxford (UK) as a postdoctoral research fellow to work on the synthesis and biological evaluation of F18-labeled ATM inhibitors under the supervision of Prof Bart Cornelissen. In 2021, he joined Ferrara lab as a postdoctoral scholar to work on the development of radiochemistry methods and the synthesis of therapeutics for medical imaging.
Senior Research Scientist-Basic Life, Rad/Molecular Imaging Program at Stanford
BioResearch Focus and interests: Molecular Imaging, PET, Immuno-Oncology, Graft versus Host Disease, CAR T cells
Dr. Israt Alam is a Senior Scientist in the Radiology Department at Stanford University. She trained in Prof. Sanjiv Sam Gambhir's lab and transitioned to Dr. Michelle James' lab in 2021. Her research focuses on studying lymphocyte activation with the motivation of developing non-invasive imaging tools, to monitor immune dynamics in response to cancer immunotherapy and in immunopathology. Her work has supported the clinical translation of several nuclear imaging agents (small molecules and a biologic) for early detection of cancer and prediction of treatment response. She has also worked on several biomarker detection platforms for early disease detection. She is currently co-chair of the "Imaging in cell and immune therapies" (ICIT) interest group for the World Molecular Imaging Society (WMIS).
-Senior Research Scientist, James Lab, Department of Radiology, Stanford
-Life Sciences Research Associate, Gambhir Lab, Department of Radiology, Stanford
-Post-Doctoral Scholar, Gambhir Lab, Department of Radiology, Stanford
-Visiting Researcher /Churchill Travel Fellow in the Plateforme d'imagerie dynamique lab of Prof. Spencer Shorte, Pasteur Institute, Paris
-Science Education Consultant: United Nations Educational, Science and Cultural Organization (UNESCO), Paris
-Science Education Intern: United Nations Educational, Science and Cultural Organization (UNESCO), Paris
Vikram S Bajaj
Adjunct Professor, Rad/Molecular Imaging Program at Stanford
BioAdj. Professor, Stanford Radiology.
Managing Director, Foresite Capital Management
Co-Founder/CEO, Foresite Labs
Chief Scientific Officer, GRAIL
Chief Scientific Officer and Co-Founder, Verily (Google Life Sciences)
Assistant Professor of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsThe focus of my research is to develop novel imaging and treatment strategies to detect and better manage cancer. This approach relies first on the identification and validation of molecular targets and biomarkers that are linked with underlying the underlying biology driving the initiation and progression of cancers. We then develop novel small molecule based radiotracers to monitor fundamental molecular and cellular processes occurring in living subjects using positron emission tomography (PET) with the goal of improving cancer diagnosis and management. We additionally develop novel peptide based theragnostic agents for stratification of patients with high receptor expression, treatment with targeted radionuclide therapy, and subsequent monitoring of treatment response. Our overall goal is to develop multiple clinically translatable strategies to improve cancer diagnosis, management, and outcomes.
Baker Family Director of Stanford ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.
Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.
The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.
Director, Small Animal Imaging Facility at Porter Drive, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordDirector, SCI3@Porter or the Canary Core Preclinical Imaging Facility at Stanford
Associate Professor of Materials Science and Engineering, Senior Fellow at the Precourt Institute for Energy and Associate Professor, by courtesy, of Radiology
BioJennifer Dionne is the Senior Associate Vice Provost of Research Platforms/Shared Facilities and an Associate Professor of Materials Science and Engineering and of Radiology (by courtesy) at Stanford. Jen received her Ph.D. in Applied Physics at the California Institute of Technology, advised by Harry Atwater, and B.S. degrees in Physics and Systems & Electrical Engineering from Washington University in St. Louis. Prior to joining Stanford, she served as a postdoctoral researcher in Chemistry at Berkeley, advised by Paul Alivisatos. Jen's research develops nanophotonic methods to observe and control chemical and biological processes as they unfold with nanometer scale resolution, emphasizing critical challenges in global health and sustainability. Her work has been recognized with the Alan T. Waterman Award (2019), an NIH Director's New Innovator Award (2019), a Moore Inventor Fellowship (2017), the Materials Research Society Young Investigator Award (2017), Adolph Lomb Medal (2016), Sloan Foundation Fellowship (2015), and the Presidential Early Career Award for Scientists and Engineers (2014), and was featured on Oprah’s list of “50 Things that will make you say ‘Wow!'"
Assistant Professor (Research) of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsDr. Durmus' research focuses on applying micro/nano-technologies to investigate cellular heterogeneity for single-cell analysis and personalized medicine. At Stanford, she is developing platform technologies for sorting and monitoring cells at the single-cell resolution. This magnetic levitation-based technology is used for wide range of applications in medicine, such as, label-free detection of circulating tumor cells (CTCs) from blood; high-throughput drug screening; and rapid detection and monitoring of antibiotic resistance in real-time. During her PhD, she has engineered nanoparticles and nanostructured surfaces to decrease antibiotic-resistant infections.
Professor of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsMy focus is image-guided drug and gene delivery and I am engaged in the design of imaging devices, molecularly-targeted imaging probes and engineered delivery vehicles, drawing upon my education in biology and imaging physics and more than 20 years of experience with the synthesis and labeling of therapeutic particles. My laboratory has unique resources for and substantial experience in synthetic chemistry and ultrasound, CT, MR and PET imaging.
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.
Postdoctoral Scholar, Molecular Imaging Program at Stanford
Current Research and Scholarly InterestsCurrent research projects include the development of:
1) Gastrin-releasing peptide receptor (GRPR) targeted radiotheranostics (Cu-64, Ga-68, Tb-161, Lu-177, amongst others)
2) Radiohybrid-based cholecystokinin-2 receptor (CCK-2R) targeted radiotheranostics (F-18, Lu-177)
3) Radiotherapeutics for targeted alpha-particle therapy
4) Radiotheranostics for novel targets
All projects have a strong focus on clinical translation